Summary & Overview
HCPCS Level II S0189: Testosterone Pellet, 75 mg
HCPCS Level II code S0189 denotes a 75 mg testosterone pellet, a dosage-specific implant formulation used in hormone replacement therapy. This code is relevant nationally for tracking utilization, billing for medication implants, and ensuring consistent coding for outpatient administration of testosterone pellets. As many systems move toward precise coding for pharmaceuticals and implantable therapies, accurate use of S0189 supports clinical documentation, claims processing, and monitoring of therapy patterns.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and clinical context for the code, typical sites of service, common modifiers associated with similar service lines, and which payers commonly cover this service. The publication outlines benchmark considerations and coding practice implications relevant to reimbursement and compliance across major commercial payers and Medicare.
This summary equips billing managers, clinical coders, and policy analysts with a national perspective on the clinical purpose of the code, operational settings where the service is performed, and the payer landscape to consider when processing claims or reviewing coding policies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S0189 describes Testosterone pellet, 75 mg. This code represents a dosage-specific pharmaceutical implant formulation of testosterone intended for hormone replacement therapy. The service type is medication administration of a testosterone pellet formulation. The typical site of service for insertion of a testosterone pellet is an outpatient clinic or office setting where minor procedures and medication implantations are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult assigned male at birth presenting for long‑term testosterone replacement for hypogonadism. After evaluation including serum total testosterone levels, symptoms review (fatigue, low libido, decreased muscle mass), and shared decision‑making about delivery methods, the clinician selects subcutaneous testosterone pellet insertion using S0189 (testosterone pellet, 75 mg). The procedure is usually performed in an outpatient clinic, ambulatory surgical center, or office procedure room under local anesthesia. Workflow: preprocedural consent and medication reconciliation → confirm recent labs and absence of contraindications (e.g., active prostate cancer) → sterile prep and local anesthetic infiltration → small incision and subcutaneous placement of one or more pellets (each billed as S0189 per 75 mg pellet) into the buttock or hip region → wound closure with adhesive or suture and sterile dressing → post‑procedure observation and discharge instructions with scheduled follow‑up for symptom assessment and serum testosterone monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work or complexity substantially exceeds typical pellet insertion (rare) |